Sanofi Mounts Offensive For Eloxatin

By Sam Schulz

Law360, New York (July 25, 2007, 12:00 AM ET) -- Eloxatin is once again the subject of heavy litigation now that Sanofi-Aventis U.S. LLC has slammed generics makers with patent infringement suits over the hit colon cancer drug, just days after one of the companies sued for declaratory judgment to keep itself out of court.

Sanofi filed similar suits against Australian drug maker Mayne Pharma and India-based Sun Pharmaceutical Industries Ltd. in the New Jersey district court Monday, saying the generic heavyweights had filed Abbreviated New Drug Applications in violation of Sanofi's patents for the drug....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles